Most recently, Matsuda et al. found RS9, a novel NFE2L2 activator, can induce the expression of NFE2L2-targeted genes, including NQO1 and GCLC, and ameliorate the symptoms of dry eye, implying the important role of NFE2L2 in the development of dry eye disease 31. Here, NFE2L2 is linked to dry eye syndrome.